A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

Jeffrey P. Sharman1 | Juliana M. L. Biondo2 | Michelle Boyer3 | Kirsten Fischer4 | Michael Hallek4 | Dingfeng Jiang5 | Arnon P. Kater6 | Michele Porro Lurà7 | William G. Wierda8

1 Department of Medical Oncology, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, Oregon, USA
2 Genentech, Inc., South San Francisco, California, USA
3 Roche Products Limited, Welwyn Garden City, UK
4 University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Germany
5 AbbVie, North Chicago, Illinois, USA
6 Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands
7 F. Hoffmann-La Roche Ltd, Basel, Switzerland
8 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Correspondence Jeffrey P. Sharman, Willamette Valley Cancer Institute and Research Center, US Oncology Research, 520 Country Club Road, Eugene, OR 97401, USA. Email: Jeff.Sharman@USONCOLOGY.COM

Abstract
We reviewed the literature (January 2010–June 2021) on the effectiveness of debulking strategies before venetoclax initiation in patients with chronic lymphocytic leukemia to reduce tumor burden, downgrade tumor lysis syndrome (TLS) risk, and avoid hospitalization. Low TLS incidence and reduced TLS risk based on tumor burden were reported following debulking in clinical trials. Real-world observational studies reporting debulking regimens recorded no TLS events, and those without debulking strategies had greater TLS incidence. Debulking prior to venetoclax considerably reduces TLS incidence. Further clinical trials and real-world studies may provide additional evidence on effectiveness of debulking in reducing TLS incidence and hospitalization need.

KEYWORDS chronic lymphocytic leukemia, debulking, hospitalization, tumor lysis syndrome, venetoclax

1 INTRODUCTION
Treatment outcomes for patients with chronic lymphocytic leukemia (CLL) have improved with the availability of targeted therapies, including the highly selective, potent, and orally bioavailable B-cell lymphoma 2 inhibitor, venetoclax [1–4]. Venetoclax has been shown to be effective and well-tolerated for both the first-line treatment of CLL and for relapsed/refractory (R/R) CLL [5–9]. Venetoclax potently induces CLL cell apoptosis and therefore is associated with risk for tumor lysis syndrome (TLS; a life-threatening metabolic disorder [if not anticipated, monitored, and treated appropriately] that occurs when tumor cells undergo rapid disintegration, releasing their intracellular contents.
into the systemic circulation) during treatment initiation. Patients treated with venetoclax should be stratified by TLS risk and receive prophylactic measures, per the label guidance, as well as monitoring throughout treatment so that occurrences of TLS are identified early and can be managed (Table 1) [10, 11]. Information on the diagnosis and classification of TLS is provided in Supplementary Table S1. Development and adoption of a gradual venetoclax ramp-up following initiation at a low dose of 20 mg daily, with risk-based monitoring and interventions based on tumor burden, has mitigated events of clinical TLS and reduced the number of laboratory TLS events (Supplementary Tables S2 and S3). Further, “debulking” (to reduce as much of the volume/bulk of cancer cells as possible) with chemotherapy, immunochemistry, or targeted therapy treatment cycles prior to initiating venetoclax can potentially reduce tumor burden and, consequently, the need for hospitalization (by downgrading high-risk tumor burden to medium- or low-risk or medium-risk with creatinine clearance [CrCl] < 80 mg/dl to low-risk for TLS; Supplementary Table S2). Thus, debulking has helped to combat the severity and reduce the incidence of TLS [12–17]. Despite these mitigating measures, there is still a risk of TLS, which may potentially increase in incidence as venetoclax becomes more widely used in real-world settings [18].

The aim of the current review was to investigate the impact of debulking strategies prior to venetoclax initiation, especially their efficacy in reducing tumor burden and the need for hospitalization.

2 | LITERATURE REVIEW

2.1 | Search strategy

A comprehensive literature search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was undertaken from November 2020 to June 2021. The search used the free-text terms “venetoclax,” “chronic lymphocytic leukemia,” “tumor lysis syndrome” and “debulking,” along with their other derivatives (ABT-199, GDC-0199, RG-7601) and abbreviations (CLL, TLS).

2.2 | Screening and selection of studies

Studies were eligible for inclusion if they were written in English and published between January 2010 and June 2021 in peer-reviewed
journals. Abstracts for presentations at scientific meetings (American Society for Clinical Oncology, American Society of Hematology, European Hematology Association, and International Conference on Malignant Lymphoma were also included.

After removing all duplicates, the initial search yielded 4475 results. Reviews, preclinical studies, case studies, and all articles that failed to mention both venetoclax and patients with CLL, as well as TLS and/or debulking, were then excluded. In total, 168 articles and abstracts were reviewed for relevance, of which 43 have been included in this review. Overall, 16 clinical trials (eight in patients with previously untreated CLL, three in patients with R/R CLL, and five reporting data for both groups) and 10 studies reporting real-world data are covered by the 43 articles and abstracts.

3 DEBULKING FOR REDUCTION OF TLS RISK

3.1 Debunking strategies utilized and reported rates of TLS in clinical trials

In clinical trials, tumor debulking was most commonly achieved using obinutuzumab, ibrutinib, or bendamustine; however, other treatments were investigated, including umbralisib and ublituximab (U2), duvelisib, and acalabrutinib (Table 2). Notably, the timing of debulking varied significantly between clinical trials, occurring within the same cycle as venetoclax initiation in some studies and starting up to three cycles prior to venetoclax in others. No TLS-related deaths were observed, and only low numbers of TLS events (very few of which were clinical) were reported following debulking regimens in clinical trials of venetoclax (Table 3).

Across studies of patients who received debulking with obinutuzumab prior to initiation of venetoclax, the aggregated number of clinical and/or laboratory TLS events was 18 in 502 patients (3.4%) [8, 9, 19–25]. Two events (11.1%) were clinical (both during debulking); 13 (72.2%) were laboratory (four during debulking, three following debulking but prior to venetoclax, five during venetoclax ramp-up, and one during combination treatment); and three (16.7%) were unclassified (timing of occurrence is not reported). Similarly, both clinical and laboratory TLS (one clinical [during venetoclax ramp-up]; 10 laboratory [nine during debulking and one during venetoclax treatment]; and two unclassified [both during debulking]) were reported for 13/182 (7.1%) patients who received debulking with bendamustine (monotherapy or combined with obinutuzumab or rituximab) prior to initiation of venetoclax [24–28].

Studies that included debulking with ibrutinib prior to initiation of venetoclax reported no cases of clinical TLS; laboratory TLS was reported for 5/338 (1.5%) patients (TLS definition was study-dependent; therefore, Cairo–Bishop or Howard criteria were used, depending on the study, and timing of occurrence was only reported for one event [during venetoclax treatment]) [29–42]. Alternative debunking regimens employing novel targeted agents (including U2, duvelisib, and zanubrutinib plus obinutuzumab) were also evaluated; these studies, which included a combined total of 82 patients, did not report any TLS events with venetoclax [43–47].

3.2 Effect of debunking on TLS risk reported in clinical trials

Several clinical trials have indicated a reduction in TLS risk following debunking, compared with baseline risk, highlighting the effectiveness of including a debunking regimen prior to initiation of venetoclax (Table 3).

3.2.1 Obinutuzumab

In the Phase 3 CLL14 trial, patients were assessed by absolute lymphocyte count (ALC) for their TLS risk at baseline (prior to any study drug being administered). Overall, in the venetoclax–obinutuzumab arm, median ALC decreased from $55 \times 10^9$ cells/L at baseline to $1.27 \times 10^9$ cells/L (range: 0.2–83.7) on Cycle 1, Day 15 [48], indicating a reduction in TLS risk following obinutuzumab debunking (see the Appendix for further information on TLS risk from a later ad hoc analysis).

TLS risk reduced markedly in the Phase 2 Dutch-Belgian Cooperative Trial Group for Hemato-oncology (HOVON) 139/GIVe trial following debunking with two cycles of obinutuzumab monotherapy: 28% of patients were high risk, and 60% were medium risk prior to debunking; following debunking, only 1% of patients were high risk, and 15% were medium risk [49]. In the Phase 3b M16-788/CLL-076 trial, medium and high TLS risk (73% and 26% of patients, respectively) at baseline were mainly driven by increased $\geq 25 \times 10^9$ cells/L in 85% of patients) [24]. The median decrease in lymph node size was 0.5 cm for obinutuzumab monotherapy [24]. After two cycles of debunking therapy, low TLS risk was achieved in 56/61 (92%) patients treated with Obinutuzumab [24]. This reduction in TLS risk may facilitate outpatient venetoclax initiation and thus reduce the need for hospitalization.

3.2.2 Obinutuzumab–bendamustine

In the Phase 3b M16-788/CLL-076 trial, low TLS risk was achieved in 20/26 (77%) patients after two cycles of debunking with obinutuzumab–bendamustine. The median decrease in lymph node size was 3 cm for obinutuzumab–bendamustine from baseline to Cycle 2; this reduced further with more cycles of debunking [24].

3.2.3 Obinutuzumab–Bruton’s tyrosine kinase inhibitor

Debulking with two cycles of obinutuzumab–zanubrutinib reduced TLS risk in the Phase 2 BOVen trial; 15/17 (88%) patients classified as
| Study | Trial number | Phase | Setting (TN, R/R, etc.) | Debulking regimen including duration | Venetoclax regimen | Overall duration | No. pts |
|-------|--------------|-------|------------------------|--------------------------------------|--------------------|-----------------|---------|
| CLL14 [9] | NCT02242942 | 3     | TN                     | G for 21 days (IV infusion 100 mg Day 1, Cycle 1 and 900 mg Day 2, Cycle 1 [or 1000 mg Day 1, Cycle 1]; 1000 mg Days 8 and 15, Cycle 1) | 5-week Ven ramp-up started Day 22, Cycle 1 (20, 50, 100, 200, and 400 mg/day), then Ven (400 mg/day) until end of Cycle 12 | Twelve cycles (VenG for six [28-day] cycles, Ven monotherapy for six cycles) | 212 |
| HOVON 139/Give [19, 49] | The Netherlands | 2     | TN | Two cycles of G monotherapy (Cycle 1, Day 1: 100 mg; Day 2: 900 mg; Day 8: 1000 mg; Day 15: 1000 mg; Cycle 2, Day 1: 1000 mg) | Ven weekly ramp-up (20, 50, 100, 200, and 400 mg/day) started in Cycle 3, then followed with 400 mg/day | Two cycles of G, six cycles of VenG (Ven 400 mg daily, G Cycles 3–8 Day 1: 1000 mg) then Ven monotherapy for six cycles (Cycles 9–14: 400 mg/day). After that, pts in partial or full remission received maintenance with 12 cycles of Ven | 65 |
| GP28331 [20] | NCT01685892 | 1b    | TN and R/R | G for 21 days (100 mg Day 1, 900 mg Day 2, 1000 mg Days 8 and 15) | Ven ramp-up with weekly dose increases to target dose (cohort 1: 100 mg; cohort 2: 200 mg; cohort 3: 400 mg; cohort 4: 600 mg) | VenG for six (28-day) cycles, followed by Ven monotherapy until PD, unacceptable toxicity, or death in R/R pts or 1-year fixed treatment in TN pts | 75 |
| Rogers et al. Blood [21, 22] | NCT02427451 | 1b/2 | TN and R/R | Two cycles of G (1000 mg IV given on Days 1-2 [split dose], 8 and 15 of Cycle 1 and Day 1 of Cycle 2). During Cycle 2 pts also received Ibr 420 mg/day orally | Ven started on Day 1, Cycle 3 at 20 mg orally daily, with dose ramp-up every 7 days to 50, 100, 200, and 400 mg. Ven continued through Cycle 14 | One cycle of G alone, one cycle of Ibr + G, six cycles of Ven + Ibr + G, then six cycles of Ibr + Ven. Ibr could be continued after Cycle 14 (investigator's discretion) | 37 |
| AVO [23] | NCT03580928 | 2     | TN | One cycle with acalabrutinib (100 mg), then two cycles of acalabrutinib + G (100 mg Day 1, 900 mg Day 2, and then 1000 mg Days 8 and 15 of Cycle 1, and Day 1 of Cycles 2–6) | Ven ramp-up (from 20 mg to 400 mg) beginning at Cycle 4 | One cycle of acalabrutinib, two cycles of acalabrutinib + G (AO) three cycles of triplet AO + Ven (AVO) therapy, then acalabrutinib + Ven (AV doublet) through Cycle 15 | 37 |
| M16-788/CLL-076 [24, 25] | NCT03406156 | 3b    | TN | Two to six cycles of G or BG | 5-week Ven ramp-up at the beginning of VenG for 5 months | Two to six cycles of debulking, VenG for 5 months, then Ven monotherapy for up to 53 weeks | 110 |

(Continues)
| Study | Trial number | Phase | Setting (TN, R/R, etc.) | Debulking regimen including duration | Venetoclax regimen | Overall duration | No. pts |
|-------|--------------|-------|--------------------------|--------------------------------------|-------------------|-----------------|---------|
| CL2-BAG [26, 27] | NCT02401503 | 2     | TN and R/R               | Two cycles of B (70 mg/m² IV on Days 1 and 2 for pts with ALC ≥ 25 × 10⁹ cells/L and lymph nodes > 5 cm in diameter), then one cycle of G (1000 mg IV on Days 1, 2, 8, and 15) | Weekly dose escalation of Ven over 5 weeks (20, 50, 100, 200, and 400 mg/day) | Two cycles of B (pts with ALC ≥ 25 × 10⁹ cells/L and lymph nodes > 5 cm in diameter), one cycle of G, five cycles of VenG, then up to 24 months of maintenance with VenG (Ven 400 mg daily with G 1000 mg every 12 weeks) | 66 |
| GO28440 [28] | NCT01671904 | 1b    | TN and R/R               | One cycle of B 90 mg/m² (TN) or 70 mg/m² (R/R) Days 1–2 and either R (375 mg/m² Day 1) or G (100 mg Day 1, 900 mg Day 2, and 1000 mg Days 8 and 15) | Ven initiated using a weekly ramp-up to target dose (cohort 1: 100 mg; cohort 2: 200 mg; cohort 3: 400 mg). | One cycle of BR followed by five cycles of Ven + BR or one cycle of BG, followed by five cycles of Ven + BG (Ven-BR: 60; Ven-BG: 22) | 82b |
| GLOW [50] | NCT03462719 | 3     | TN                       | Three (28-day) cycles of Ibr (420 mg/day) | 5-week ramp-up of Ven (beginning at 20 mg to 400 mg) starting on Day 1, Cycle 4, then Ven 400 mg/day | Fifteen cycles (three cycles of Ibr monotherapy, then Ibr + Ven for 12 cycles) followed by Ibr alone until PD or unacceptable toxicity | 106 |
| CAPTIVATE [29–35] | NCT02910583 | 2     | TN                       | Three (28-day) cycles of Ibr (420 mg/day) | 5-week ramp-up (Ven 20, 50, 100, 200, and 400 mg/day) starting on Day 1, Cycle 4, then Ven 400 mg/day | Ibr + Ven for 12 (28-day) cycles, or until PD or unacceptable toxicity | 164 |
| Jain et al. N Engl J Med [36] | NCT02756897 | 2     | TN, high-risk and older pts | Three (28-day) cycles of Ibr (420 mg/day) | Weekly Ven dose escalation to 400 mg/day starting on Day 1, Cycle 4 | 27 cycles (three cycles of Ibr monotherapy, then Ibr + Ven for 24 cycles) followed by Ibr alone until PD or unacceptable toxicity | 75 |
| Thompson et al. Blood [37, 38] | NCT03128879 | 2     | Pts with high-risk disease (TN or R/R) | Pts receiving Ibr therapy for ≥ 1 year | Weekly dose escalation of Ven (beginning at 20 mg/day, until 400 mg/day target reached) | Ibr + Ven could continue for up to 2 years | 45 |
| CLARITY [39–42] | ISCRTN: 13751862 | 2     | R/R                      | 8 weeks of Ibr (420 mg/day) | Ven starting on Day 1, Week 9, Weekly dose ramp-up from 10 mg/day for first three pts and 20 mg/day for all other pts (20, 50, 100, 200, and 400 mg/day) | 26 months (Ibr monotherapy for 2 months, Ibr + Ven for 24 months) | 54 |

(Continues)
| Study                        | Trial number | Phase | Setting (TN, R/R, etc.) | Treatment                                                                 | Venetoclax regimen                                      | Overall duration                                      | No. pts
|------------------------------|--------------|-------|-------------------------|---------------------------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|--------|
| BOVen [43, 44]               | NCT03824483  | 2     | TN                      | Two cycles of zanubrutinib (160 mg starting Day 1) plus G (1000 mg IV Day 1 [or split Days 1–2] Day 8 and 15 of Cycle 1, then Day 1 of Cycles 2–8) | Ven 5-week ramp-up initiated Cycle 3, Day 1 (beginning at 20 mg and increasing to 400 mg orally daily) | 39                                                  |        |
| U2-Ven [45]                  | NCT03379051  | 1/2   | R/R                     | Three cycles of Umbra daily along with Ubli, administered weekly during Cycle 1, then once during Cycles 2 and 3 | Ven ramp-up to 400 mg in Cycle 4, given with Umbra for 9 cycles | Twelve cycles (three cycles for debulking, Umbra + Ven for nine cycles) | 21     |
| Crombie et al. Blood [46, 47]| NCT03534323  | 1     | R/R                     | Duvelisib twice daily for 7 days                                         | Ven started on Day 8 (at 10 mg/day, with weekly ramp-up to 20, 50, 100, 200, and 400 mg; last three pts initiated Ven at 20 mg), given with duvelisib | 22                                                  |        |

Abbreviations: B, bendamustine; G, obinutuzumab; Ibr, ibrutinib; IV, intravenous; No., number; PD, disease progression; pts, patients; R, rituximab; R/R, relapsed/refractory; TN, treatment naïve, Ubli, ublituximab; Umbra, umbralisib; Ven, venetoclax.

*Numbers represent only patients treated with venetoclax, patients treated in the control arm of randomized studies are not included within this count, neither are patients who did not receive study drug or did not initiate venetoclax;*

*Includes patients treated with Schedule A (no debulking) and Schedule B (debulking).*
| Clinical trial | Debulking regimen including duration | Venetoclax regimen | No. pts | TLS risk at baseline, n (%) | Total no. of pts with TLS (clinical events/laboratory events) | Occurrence of TLS (during debulking or venetoclax treatment) | TLS treatment/management | TLS outcome (e.g., resolved, required hospitalization) |
|----------------|--------------------------------------|--------------------|---------|-----------------------------|-------------------------------------------------|----------------------------------------------------------|--------------------------|-----------------------------------------------|
| CLL14 [9]      | G for 21 days (IV infusion 100 mg Day 1, Cycle 1 and 900 mg Day 2, Cycle 1 or 1000 mg Day 1, Cycle 1; 1000 mg Day 8 and 15 Cycle 1) | 5-week Ven ramp-up started Day 22, Cycle 1 (20, 50, 100, 200, and 400 mg/day), then Ven (400 mg/day) until end of Cycle 1 | 212 | Low: 29 (14) Medium: 139 (64) High: 48 (22) | 3c | NR | NR | NR |
| HOVON 139/GIVe [19, 49] | Two cycles of G monotherapy (Cycle 1 Day 1: 100 mg; Day 2: 900 mg; Day 8: 1000 mg; Day 15: 1000 mg; Cycle 2 Day 1: 1000 mg) | Ven weekly ramp-up (20, 50, 100, 200, and 400 mg/day) started in Cycle 3, then followed with 400 mg/day | 65 | Medium: 41 (62) High: 19 (29) | 6 (0/6) | Four during G debulking and two during Ven ramp-up | Protocol-mandated IV hydration and allopurinol rasburicase | All cases of TLS resolved |
| GP28331 [20] | G for 21 days (100 mg Day 1, 900 mg Day 2, 1000 mg Day 8 and 15) | Ven ramp-up with weekly dose increases to target dose (cohort 1: 100 mg; cohort 2: 200 mg; cohort 3: 400 mg; cohort 4: 600 mg) | 75 | Low: 12 (16) Medium: 41 (55) High: 22 (29) | 3 (0/4) | One laboratory TLS occurred after G but before Ven, the other three occurred during Ven ramp-up | NR | NR |
| Rogers et al. Blood [21, 22] | Two cycles of G (1000 mg IV given on Day 1–2 [split dose], 8 and 15 of Cycle 1 and Day 1 of Cycle 2). During Cycle 2 pts also received Ibr 420 mg/day orally | Ven started on Day 1, Cycle 3 at 20 mg orally daily, with dose ramp-up every 7 days to 50, 100, 200, and 400 mg. Ven continued through Cycle 14 | 37 | For TN pts (n = 25) Medium: 18 (72) High: 7 (28) | 0 | N/A | N/A | N/A |
| AVO [23] | One cycle with acalabrutinib (100 mg), then two cycles of acalabrutinib + G (100 mg Day 1, 900 mg Day 2, and then 1000 mg Day 8 and 15 of Cycle 1, and Day 1 of Cycles 2–6) | Ven-ramp-up (from 20 mg to 400 mg) beginning at Cycle 4 | 37 | NR | 2 (0/2) | Both grade 3 laboratory TLS events occurred after G, but before Ven | NR | Both pts continued G |
| M16-788/CLL-076 [24, 25] | Two to six cycles of G or BG | 5-week Ven ramp-up at the beginning of VenG for 5 months | 110 | NR | 10 (2/8) | Nine TLS events (including the two clinical TLS, five laboratory TLS, and two unclassified) during debulking, one laboratory TLS during VenG | NR | NR |

(Continues)
| Clinical trial | Debulking regimen including duration | Venetoclax regimen | No. pts | TLS risk at baseline, n (%) | Total no. of pts with TLS (clinical events/ laboratory events) | Occurrence of TLS (during debulking or venetoclax treatment) | TLS treatment/ management | TLS outcome (e.g., resolved, required hospitalization) |
|----------------|-------------------------------------|--------------------|---------|------------------------------|---------------------------------------------------------------|-----------------------------------------------------------|---------------------------|-----------------------------------------------------|
| CLL2-BAG [26, 27] | Two cycles of B (70 mg/m² IV on Days 1 and 2 for pts with ALC ≥25 × 10⁹ cells/L and lymph nodes > 5 cm in diameter), then one cycle of G (1000 mg IV on Days 1, 2, 8, and 15) | Weekly dose escalation of Ven over 5 weeks (20, 50, 100, 200, and 400 mg/day) | 66 | Low: 7 (11) Medium: 39 (59) High: 18 (27) | 3 (1/2) | One during B debulking, one in induction Cycle 1 with G, two in Cycle 3 and one in Cycle 4 with VenG | NR | NR |
| GO28440 [28] | One cycle of B 90 mg/m² (TN) or 70 mg/m² (R/R) Day 1–2 and either R (375 mg/m² Day 1) or G (100 mg Day 1, 900 mg Day 2 and 1000 mg Day 8 and 15) | Ven initiated using a weekly ramp-up to target dose (cohort 1: 100 mg; cohort 2: 200 mg; cohort 3: 400 mg). | 82 | For pts in schedule A and B (without and with debulking, respectively) Low: 16 (19) Medium: 45 (54) High: 21 (25) | 3 (1/2) | Both laboratory TLS events occurred prior to Ven. The clinical TLS event occurred on Day 29 (Day 1 of Cycle 2) after administration of Ven 50 mg | Standard-of-care measures | All TLS events resolved (both laboratory events did not lead to permanent discontinuation of any study drug) |
| GLOW [50] | Three (28-day) cycles of Ibr (420 mg/day) | 5-week ramp-up of Ven (beginning at 20 mg to 400 mg) starting on Day 1, Cycle 4, then Ven 400 mg/day | 106 | NR | NR | NR | NR | NR |
| CAPTIVATE [29–35] | Three (28-day) cycles of Ibr (420 mg/day) | 5-week ramp-up (Ven 20, 50, 100, 200, and 400 mg/day) starting on Day 1, Cycle 4, then Ven 400 mg/day | 164 | High: 39 (24) | 1 (0/1) | NR | NR | NR |
| Jain et al. N Engl J Med [36] | Three (28-day) cycles of Ibr (420 mg/day) | Weekly Ven dose escalation to 400 mg/day starting on Day 1, Cycle 4 | 75 | Low: 10 (15) Medium: 58 (72) High: 12 (13) | 3 (0/3) | NR | NR | NR |
| Thompson et al. Blood [37, 38] | Pts receiving Ibr therapy for ≥1 year | Weekly dose-escalation of Ven (beginning at 20 mg/day, until 400 mg/day target reached) | 45 | NR | 0 | N/A | N/A | N/A |

(Continues)
TABLE 3  (Continued)

| Clinical trial            | Debulking regimen including duration | Venetoclax regimen | No. pts | TLS risk at baseline, n (%) | Total no. of pts with TLS (clinical events/laboratory events) | Occurrence of TLS (during debulking or venetoclax treatment) | TLS treatment/management | TLS outcome (e.g., resolved, required hospitalization) |
|---------------------------|--------------------------------------|--------------------|---------|-----------------------------|-----------------------------------------------------------------|---------------------------------------------------------------|--------------------------|---------------------------------------------------|
| CLARITY [39–42]           | 8 weeks of Ibr (420 mg/day)          | Ven starting on Day 1, Week 9. Weekly dose ramp-up from 10 mg/day for first three pts and 20 mg/day for all other pts (20, 50, 100, 200, and 400 mg/day) | 54      | NR                          | 1 (0/1)                                                         | During 200 mg Ven dose                                         | Ven interrupted for 7 days (until biochemical abnormalities resolved) | Pt subsequently ramped up to 400 mg/d of Ven with no additional TLS |
| BOVen [43, 44]            | Two cycles of zanubrutinib (160 mg starting Day 1) plus G (1000 mg IV Day 1 [or split Day 1–2] Days 8 and 15 of Cycle 1, then Day 1 of Cycles 2–8) | Ven 5-week ramp-up initiated Cycle 3, Day 1 (beginning at 20 mg and increasing to 400 mg orally daily) | 39      | High: 17 (44)                | 0                                                              | N/A                                                             | N/A                                    | N/A                                |
| U2-Ven [45]               | Three cycles of Umbra daily along with Ubli, administered weekly during Cycle 1, then once during Cycles 2 and 3 | Ven ramp-up to 400 mg in Cycle 4, given with Umbra for 9 cycles | 21      | Low: 7 (33) Medium: 12 (57) High: 2 (10) | 0                                                              | N/A                                                             | N/A                                    | N/A                                |
| Crombie et al. Blood [46, 47] | Duvelisib twice daily for 7 days | Ven started on Day 8 (at 10 mg/day, with weekly ramp-up to 20, 50, 100, 200, and 400 mg; last 3 pts initiated Ven at 20 mg), given with duvelisib | 22      | NR                          | 0                                                              | N/A                                                             | N/A                                    | N/A                                |

Abbreviations: AE, adverse event; B, bendamustine; G, obinutuzumab; Ibr, ibrutinib; IV, intravenous; N/A, not applicable; No., number; NR, not reported; pts, patients; R, rituximab; R/R, relapsed/refractory; TLS, tumor lysis syndrome; TN, treatment naïve; Ubli, ublituximab; Umbra, umbralisib; Ven, venetoclax.

* Three laboratory AEs were reported but of these only one met Howard criteria.
* Total number of patients with TLS risk at baseline is greater than the number of patients who received venetoclax treatment.
* Number and type of TLS events are not specified.
* TLS risk for TN patients only (n = 25).
* Two patients were assessed after baseline.
* One patient had one TLS event and two patients had two TLS events each, although the type of TLS event was not specified.
* Includes patients treated with Schedule A (no debulking) and Schedule B (debulking). Sixty patients received Ven-BR (both Schedule A and B) and 22 patients received Ven-BG (both Schedule A and B).
Ibrutinib monotherapy

Bendamustine monotherapy

Real-world data on the use of debulking

3.2.4 | Ibrutinib monotherapy

Debulking with ibrutinib monotherapy in the Phase 2 CAPTIVATE trial, the Jain et al. studies and the Phase 3 GLOW trial (NCT03462719) led to the downgrading of TLS risk: 94% of patients were downgraded from high risk at baseline to medium or low risk after three cycles of ibrutinib in CAPTIVATE (secondary endpoint) [29–31]; 80% of the high-risk patients and 48% of the medium-risk patients were downgraded in the Jain et al. study following three cycles of ibrutinib monotherapy [36]; and 85% of patients were downgraded from high risk at baseline to medium or low risk after three cycles of ibrutinib in GLOW [50]. Overall, 75% of patients in CAPTIVATE avoided hospitalization for venetoclax initiation due to downgrading of their TLS risk level following debulking [32].

Although several strategies are adopted for debulking (obinutuzumab monotherapy, obinutuzumab in combination with chemotherapy or a Bruton's tyrosine kinase inhibitor, and ibrutinib monotherapy), with debulking lasting different lengths of time depending on treatment (1–3 cycles), the inclusion of debulking within a clinical trial is beneficial. Reported numbers of TLS events were low, and hospitalization for TLS was rare due to the effectiveness of debulking regimens, adherence to study protocols, and compliance with the US Prescribing Information (USPI) [51] and European Summary of Product Characteristics (SmPC) [48] recommendations for venetoclax.

3.2.5 | Bendamustine monotherapy

Debulking with two cycles of bendamustine (for patients with an ≥25 x 10^9 cells/L or lymph nodes with a diameter of > 5 cm, unless they had contraindications) in the Phase 2 CLL2-BAG trial led to a reduction in TLS risk: ALC was normalized in 31 patients and reduced by ≥50% in 37 of 44 patients after bendamustine debulking (median ALC at baseline was 57.1 x 10^9 cells/L, compared with 2.7 x 10^9 cells/L after debulking) [26]. Median ALC was further reduced after the first induction cycle (0.9 x 10^9 cells/L). TLS risk was reassessed by the treating physician for 14 patients and retrospectively by the German CLL Study Group (GCLLSG) for 21 patients. Downgrading of TLS risk category (before the start of venetoclax) from high risk to medium risk occurred for three patients by the treating physician and three by the GCLLSG and downgrading from medium risk to low risk occurred for seven patients reassessed by the treating physician and 18 by the GCLLSG.

3.3 | Real-world data on the use of debulking strategies and TLS risk with venetoclax

Although the evidence for the impact of debulking is of lower quality from real-world studies, compared with data from clinical trials, there is some indication that previous therapy can affect TLS risk in some patients within these more heterogeneous populations. These retrospective descriptive papers are summarized here to further characterize how other investigators have evaluated this strategy.

No cases of clinical or laboratory TLS have been reported in real-world studies that included debulking regimens, such as the retrospective Moffitt Cancer Center study (where patients at intermediate/high risk of developing TLS could receive debulking) [52]. Risk stratification for patients with R/R CLL at the Moffitt Cancer Center enabled 15/20 (75%) patients who were considered to be at medium or high risk of developing TLS to receive debulking therapy with rituximab, ofatumumab, or obinutuzumab prior to initiation of venetoclax [52]. Following debulking, TLS risk status was reduced to low risk in 12 patients based on reduction in ALC.

Real-world studies in the R/R setting that did not report the use of a debulking strategy appeared to be associated with a greater incidence of TLS, compared with real-world studies that used debulking, although direct comparisons across studies are not possible due to differences in study methodology. Two TLS events were reported for the UK CLL Forum (one case of clinical TLS defined by the Howard criteria, one separate case of biochemical TLS, and one case of isolated hyperphosphatemia) [53], while six patients (13%) developed laboratory TLS (three of whom also developed clinical TLS) in the Mayo clinic study [54]. Clinical TLS occurred in 2.7% of patients (n = 8), and laboratory TLS occurred in 5.7% of patients (n = 17) in the international collaboration of the CLL Collaborative Study of Real-World Evidence (CORE) and UK CLL Forum [55]. Similarly, TLS occurred in 9.7% of patients (nine clinical events) in a retrospective cohort study of R/R CLL patients treated with venetoclax across 24 US and 42 UK academic and community centers in partnership with the UK CLL Forum and the CLL CORE [56]. It is likely that these similarities in outcomes are due to overlapping patient populations, as these different real-world cohort studies (with the exception of the Mayo clinic study) all use centers from the UK CLL Forum and CORE [53, 55, 56].

Further, a UK multicenter study (170 patients from 11 centers; venetoclax monotherapy, n = 99 [58%]; venetoclax–rituximab, n = 68 [40%]; and venetoclax–obinutuzumab, n = 3 [2%]) reported seven TLS events (three clinical and four biochemical, of which six occurred in high-risk patients); however, there was no indication if these centers were the same as those in the UK CLL Forum [57]. TLS was observed in 14 (22%) patients receiving venetoclax monotherapy in a French Innovative Leukemia Organization (FILO) study of the French compassionate use cohort [58], 10 (12%) patients in an observational study conducted in Austria, Germany, and Switzerland (after receiving venetoclax–rituximab) [59], and three (6.3%) patients in a Spanish observational study where venetoclax was initiated at least 9 months before inclusion in the study (venetoclax monotherapy [81%]; venetoclax–rituximab [4%]; venetoclax–obinutuzumab [2%];
### TABLE 4  Summary of ongoing and upcoming clinical trials for debulking prior to initiation of venetoclax

| Study     | Trial number | Phase | Setting (TN, R/R, etc.) | Debulking regimen | Venetoclax regimen | Overall duration |
|-----------|--------------|-------|-------------------------|-------------------|-------------------|-----------------|
| FLAIR     | ISRCTN01844152 | 3     | TN                      | Ibr for 8 weeks   | Ven dose ramp-up for 5 weeks | Up to 6 years   |
| ERADIC    | NCT04010968   | 2     | TN fit pts with medium-risk CLL | Ibr (420 mg/day) for 3 months | Beginning at Month 4, a 5-week Ven dose ramp-up (20, 50, 100, 200, and 400 mg) then 400 mg/day continuously from Month 5 to the end of treatment, either Month 15 or Month 27 | 15 or 27 months of treatment (Ibr for 3 months, followed by Ven + Ibr) |
| Stanford  | NCT03045328   | 2     | R/R                     | Ibr daily for 8 weeks | Ven daily beginning on Week 9 Day 1 | 61 weeks (8 weeks Ibr, then 53 weeks Ibr + Ven) in the absence of PD or unacceptable toxicity |
| VISION    | NCT03226301   | 2     | R/R                     | Two cycles of Ibr (420 mg daily) | Beginning Cycle 3, pts receive Ven daily (ramp-up at start) | Ibr + Ven for 15 cycles, then Ibr until PD/relapse |
| ALLIANCE  | A041702       | 3     | TN older pts           | Two cycles of Ibr (daily) and G (IV over 4 hours on Day 1, 2, 8, and 15 of Cycle 1 and on Day 1 of Cycle 2) | Beginning Cycle 3, pts receive Ven daily | 14 cycles in the absence of PD or unacceptable toxicity (Ibr + G for two cycles, Ibr + G + Ven for 12 cycles), then one cycle of Ibr. Following this Ibr PO QD every 28 days in the absence of PD or unacceptable toxicity |
| MLS046    | NCT03701282   | 3     | TN                      | Ibr daily and G IV over 4 h on Day 1, 2, 8, and 15 of Cycle 1 and on Day 1 of Cycle 2–6 | Ven daily Cycle 3–14 | 19 cycles in the absence of PD or unacceptable toxicity |
| Columbia  | NCT03609593   | 2     | TN                      | Three cycles of B + R | 5-week dose ramp-up to 400 mg daily. VenR for 12 cycles | 15 months |

Abbreviations: B, bendamustine; CLL, chronic lymphocytic leukemia; G, obinutuzumab; Ibr, ibrutinib; IV, intravenous; PD, disease progression; PO, orally; pts, patients; QD, once a day; R, rituximab; R/R, relapsed/refractory; TN, treatment naïve; Ven, venetoclax.

Venetoclax and other agents [13%]) [60]. A total of 17 (51.5%) patients developed TLS by laboratory criteria at venetoclax doses from 20 to 400 mg, five patients developed TLS by clinical criteria, ranging from grade 0 to 3 in severity (per Cairo–Bishop definition) in the Koenig et al. Ohio State University study [61]. However, Koenig et al. used a rapid venetoclax dose escalation, with dose increases every 1 or 2 days, if tolerated. In real-world studies, information on laboratory monitoring and correct dose ramp-up administration was not always available.

Data from the CLL CORE and UK CLL Forum study (real-world studies without debulking prior to venetoclax initiation) indicate that planned hospitalizations for venetoclax administration are more frequent in patients with high TLS risk than low or medium TLS risk, in agreement with the label recommendations [55]. TLS risk classification by the investigator at the time of venetoclax initiation was high in 28%, medium in 32%, and low in 40% of patients, with at least one planned hospitalization during venetoclax dose escalation in 88%, 80%, and 56% of patients, respectively [55]. Furthermore, 65% of patients at high TLS risk had two or more planned hospitalizations during venetoclax dose ramp-up. However, on the basis of available data (ALC and lymph node measurements), the TLS risk level was misclassified in 12.5% of
patients, demonstrating a need for training and education on TLS risk determination [55].

In a real-world study where most patients had genetically high-risk CLL and were heavily pretreated (with a median of five prior lines of therapy), high tumor burden was associated with increased incidence of TLS with venetoclax treatment; 3/8 (38%) patients with low initial tumor burden prior to venetoclax without debulking developed laboratory TLS, compared with 11/20 (55%) and 3/5 (60%) patients with medium and high tumor burden, respectively [61]. The CLL CORE and UK CLL Forum cohort study of 297 patients indicated that there are other variables affecting the incidence of TLS in real-world studies in the R/R setting. These include USPI-defined CrCl ($<80$ vs. $\geq80$ ml/min [51]; multivariate analysis: odds ratio [OR] 2.6; 95% confidence interval [CI]: 1.1–6.2; $p = 0.031$) and TLS risk group prior to initiation of venetoclax (multivariate analysis, high risk vs. low risk: OR 3.0; 95% CI: 1.7–5.4; $p = 0.001$) [55]. However, when investigating whether any specific prognostic factors serve as predictors for TLS risk in routine clinical practice, no association was observed between risk of TLS and age, sex, Rai stage, fluorescence in situ hybridization (specific analysis not defined), immunoglobulin heavy chain gene mutation status, serum $\beta$-2-microglobulin, lactate dehydrogenase, ALC, or largest lymph node size [54].

3.4 Authors’ perspectives

So far, as can be seen from the results described above, we conclude that it is the effectiveness of the debulking strategy rather than any specific treatment strategy that is important with regard to reducing the risk of TLS. Of note, obinutuzumab is currently the only treatment approved in combination with venetoclax for treatment-naïve patients with CLL, with the recommendation to begin venetoclax ramp-up following three weekly doses of obinutuzumab monotherapy. Of particular interest, we have noted that TLS occurring after debulking is mainly laboratory rather than clinical TLS, and no lethal event has occurred in studies using debulking strategies prior to applying veneto-clax. Furthermore, few instances of TLS have been reported for either treatment-naïve or R/R patients with CLL after a debulking strategy has been used, suggesting that line of therapy is not indicative of a higher risk of a TLS event.

The definitions of tumor burden based on lymph node size and leukocytosis, established early in venetoclax development, are still used today. Based on the vast amount of experience and well-documented cases from clinical trials, the aim of future studies should be to re-determine risk factors for TLS, with more reliance placed on radiology for review of scans, in particular for determination of the extent of adenopathy. Ongoing and upcoming clinical trials (Table 4) may help to provide further evidence on the utility of debulking in reducing TLS risk. Future clinical trials incorporating accelerated ramp-ups (conducted in experienced academic centers with close inpatient monitoring) will provide further insights into patient subgroups with R/R CLL who could benefit from shorter ramp-up regimens, despite the greater risk of TLS associated with venetoclax dose escalations shorter than 5 weeks. Additionally, further real-world studies where debulking is incorporated into routine practice for patients who are deemed to be at high risk of TLS will help to show the effectiveness of debulking in reducing the incidence of TLS and the need for hospitalization. Education on correct monitoring procedures during venetoclax initiation and management of TLS events, as well as the use of debulking strategies and evaluation of TLS risk, can continue to help reduce TLS incidence in real-world practice.

4 CONCLUSION

Debulking strategies have resulted in reduced tumor burden and shifts in classification from high to lower TLS risk prior to venetoclax initia-
tion. This in turn has strongly decreased rates of clinical and lethal TLS events and also reduced the need for hospitalization for veneto-clax dosing in clinical studies. The importance to adhere to the 5-week ramp-up monitoring was recently reemphasized with the inclusion of more detailed guidance in the SmPC aligning to the USPI. This suggests that although mitigation of TLS risk with venetoclax is achieved by adherence to the established venetoclax initiation protocol (five weekly dose ramp-up schedule, TLS prophylaxis, and monitoring measures), some improvement in aligning outpatient procedures with the measures recommended in the label is required. Nevertheless, debulking prior to the initiation of venetoclax may provide the opportunity for carefully selected patients to start venetoclax therapy in the outpatient setting.

ACKNOWLEDGMENTS

Venetoclax is being developed in a collaboration between Genentech, Inc. and AbbVie. F. Hoffmann-La Roche Ltd. provided financial support for this literature review. Third-party medical writing assistance, under the direction of the authors, was provided by Rachel Dobb, PhD, of Ashfield MedComms, an Ashfield Health company, funded by F. Hoffmann-La Roche Ltd.

AUTHOR CONTRIBUTION

All authors were involved in the conception and design of the literature search, analysis and interpretation of the included publications, and the writing, review, and revision of the manuscript.

CONFLICT OF INTEREST

Jeffrey P. Sharman reports stock options with Centessa Pharmaceuticals; consultancy with AbbVie, AstraZeneca, Beigene, Bristol Myers Squibb, Lilly, Pharmaceuticals, and TG Therapeutics; and membership on board of directors or advisory committees for Centessa Pharmaceuticals. Juliana M.L. Biondo is an employee of Genentech, Inc. and has stock ownership for F. Hoffmann-La Roche Ltd. Michelle Boyer is an employee of F. Hoffmann-La Roche Ltd. Kirsten Fischer received honoraria and held a consulting/advisory role from F. Hoffmann-La Roche Ltd. Michael Hallek received grants, non-financial support and personal fees (honoraria,
speaker’s bureau and/or advisory board) from AbbVie, Celgene, F. Hoffmann-La Roche Ltd, Gilead, Mundipharma, Janssen, and Pharmacetics. Dingfeng Jiang is an employee of AbbVie; and may own AbbVie stock or stock options. Arnon P Kater has held a consultant or advisory role for Biogeneration and LAVA; received honoraria from Celgene, F. Hoffmann-La Roche Ltd./Genentech, Inc., AstraZeneca, and Janssen; and received research funding from Celgene, F. Hoffmann-La Roche Ltd./Genentech, Inc., AstraZeneca, and Janssen. Michele Porro Lurá is an employee of F. Hoffmann-La Roche Ltd; and has stock ownership for F. Hoffmann-La Roche Ltd. William G. Wierda is employed by The University of Texas MD Anderson Cancer Center; and received research funding from AbbVie and Genentech, Inc.; received travel accommodation and expenses from AbbVie and Genentech, Inc.

ETHICS STATEMENT
No experiments were performed on humans or animals, only previously published data were included.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study. All information discussed within the literature review is derived from articles and abstracts published between January 2010 and June 2021. As such, the data are all included within the manuscript and referenced accordingly.

REFERENCES

1. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1525–37.
2. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia, P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukaemia. N Engl J Med. 2015;373(25):2425–37.
3. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hilm'en P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
4. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.
5. Seymour JF, Kips TJ, Eichhorst B, Hilm'en P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20.
6. Kater AP, Seymour JF, Hilm'en P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukaemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269–77.
7. Kater AP, Wu QJ, Kips T, Eichhorst B, Hilm'en P, D’Rozario J, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38(34):4042–54.
8. Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36.
9. Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink A-M, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–200.
10. Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020;(1):357–62.
11. Gribben JG. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020;188(6):844–51.
12. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116(8):546–54.
13. Rampillo E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nature clinical practice Oncology 2006;3(8):438–47.
14. Nauffal M, Redd R, Ni J, Stone RM, DeAngelo DJ, McDonnell AM. Single 6-mg dose of rasburicase: the experience in a large academic medical center. J Oncol Pharm Pract. 2019;25(6):1349–56.
15. Jeha S. Tumor lysis syndrome. Semin Hematol. 2001;38(S10):4–8.
16. Sharman JP, Andorsky D, Melear JM, Sanda Anz BM III, Kolibaba KS, et al. Debukling eliminates need for hospitalization prior to initiating frontline venetoclax therapy in previously untreated CLL patients: a phase 3b study. Blood. 2019;134(S1):3042.
17. Annemans L, Moeremans K, Lamotte M, Conde JG, van den Berg H, Myint H, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer. 2003;11(4):249–57.
18. Anderson M, Seymour J. Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL? Leuk Lymphoma. 2020;61(10):2286–8.
19. Levin M-D, Kersting S, Nasserinejad K, Dubois J, Dobber J, Mellink C, et al. Obinutuzumab and venetoclax in untreated unfit patients with chronic lymphocytic leukemia. HemaSphere. 2020;4(51):299–300.
20. Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765–75.
21. Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018;132(15):1568–72.
22. Rogers KA, Huang Y, Stark A, Awan FT, Maddocks KJ, Woyach JA, et al. Initial results of the phase 2 treatment naïve cohort in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia. Blood. 2017;130(S1):431.
23. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood. 2019;134(S1):32.
24. Sharman J, Andorsky D, Melear J, Sanda Anz B III, Kolibaba K, et al. Phase 3b study to evaluate debukling regimens prior to initiating venetoclax therapy in untreated patients with chronic lymphocytic leukemia. HemaSphere. 2020;4(S1):299.
25. Sharman J, Andorsky D, Melear J, Sanda Anz B III, Kolibaba K, et al. CLL-076: Phase 3b study to evaluate debukling regimens prior to initiating venetoclax therapy in untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2020;38(34):4042–54.
CLL2-BAG trial of the German CLL study group (GCLLSG). Oncol Res Treat. 2017;35(S2):25–7.

28. Stilgenbauer S, Morschhauser F, Wendtner CM, Cartron G, Hallek M, Eccherst B, et al. Venetoclax plus bendamustine–rituximab or bendamustine–obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). Haematologica. 2021;106(11):2384–44.

29. Allan JN, Wierda WG, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Primary analysis of the fixed-duration cohort from the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma. HemaSphere. 2021;5(S2):27–8.

30. Ghia P, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-dose (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of the FD cohort of the phase 2 compassionate study. J Clin Oncol. 2021;39(S1):7501.

31. Tam CSL, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Captivate primary analysis of first-line treatment with fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Hematol Oncol. 2021;39(S2):66–8.

32. Siddiqi T, Tam CS, Allan JN, et al. First-line ibrutinib (IBR) + venetoclax (VEN) for patients (PTS) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Efficacy and safety results from captivate MRD cohort. HemaSphere. 2020;4(S1):32–3.

33. Tam CS, Siddiqi T, Allan JN, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib (ibr) plus venetoclax (ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study. Blood. 2019;134(S1):35.

34. Ghia P, Tam C, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, et al. Ibrutinib lead-in followed by venetoclax in patients with chronic lymphocytic leukemia: Phase 2 compassionate study. HemaSphere. 2018;2(S1):351.

35. Wierda WG, Siddiqi T, Flinn I, Badoux XC, Kipps TJ, Allan JN, et al. Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). J Clin Oncol. 2018;36(S1):7502.

36. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Venetoclax monotherapy for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–103.

37. Thompson PA, Ferrajoli A, Jain N, Wang Y, Peterson CB, Garg N, et al. The addition of venetoclax to ibrutinib achieves a high rate of undetectable minimal residual disease in patients with high-risk CLL. Blood. 2020;136(S1):28–9.

38. Thompson PA, Keating MJ, Jain N, Ferrajoli A, Kadia TM, Pose P, et al. Venetoclax added to ibrutinib in high-risk CLL achieves a high rate of undetectable minimal residual disease. JCO. 2019;37(30):2722–29.

39. Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722–29.

40. Munir TR, Rawstron A, Brock K, Muñoz-Vicente S, Yates F, Bishop R, et al. Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the blood-wise tap clarity study. Br J Haematol. 2019;185(S1):25.

41. Munir TR, Munir T, Rawstron A, Brock K, Muñoz-Vicente S, Yates F, et al. Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (bloodwise tap clarity study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. Br J Haematol. 2018;181(S1):34–5.

42. Muñoz-Vicente S, Bishop R, Hillmen P, Munir T, Rawstron A, Brock K, et al. The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy. Haematologica. 2017;102(S1):311.

43. Soumerai JD, Mato A, Carter J, Dogan A, Hochberg A, Barnes JA, et al. Initial results of a multicenter, investigator-initiated study of MRD-driven time limited therapy with zanubrutinib, obinutuzumab and venetoclax. HemaSphere. 2020;4(S1):35.

44. Soumerai JD, Mato AR, Carter J, Dogan A, Hochberg A, Barnes JA, et al. Initial results of a multicenter, investigator-initiated study of MRD-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax. J Clin Oncol. 2020;38(S15):8006.

45. Barr PM, Hill BT, Ma S, Baran AM, Bui A, Meacham P, et al. A phase I/II study of umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2019;134(S1):360.

46. Cymbie JL, Tyekucheva S, Wang Z, Savell A, Brennan N, Lowney J, et al. Updated results from a phase I/II study of duvelisib and venetoclax in patients with relapsed or refractory CLL/SLL or Richter’s syndrome. Blood. 2020;136(S1):46–7.

47. Cymbie J, Tyekucheva S, Savell A, Francoeur K, Choiniere M, Montegaard J, et al. A phase I study of duvelisib and venetoclax in patients with relapsed or refractory CLL/SLL with the addition of rituximab. Blood. 2020;136(S1):46–7.

48. Venclyxo: Summary of product characteristics. AbbVie Inc. Available from: https://www.ema.europa.eu/en/documents/product-information/venclyxo-epar-product-information_en.pdf.

49. Levin M-D, Dubois J, Nasserinejad K, Dobber J, Mellink C, van der-Kersemaekers A-MK, et al. MRD-guided or fixed 12 cycles of venetoclax consolidation after venetoclax plus obinutuzumab treatment in first-line FCR unfit patients with CLL: Primary endpoint analysis of the HOVON 139/GIVE trial. HemaSphere. 2021;5(S2):29.

50. Kater A, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (Clb+O) for first-line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study. HemaSphere. 2021;300172:LB1902.

51. VENCLEXTA (Venetoclax). Abbvie Inc. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208573s026lbl.pdf.

52. Grajales-Cruz AF, Chavez J, Volpe VO, Sandoval-Sus J, Shah B, Bello C, et al. Venetoclax in relapsed/refractory chronic lymphocytic leukemia: A retrospective, single-institution analysis based on risk features and debulking strategy with anti-cd20 monoclonal antibody. Blood. 2019;134(S1):5484.

53. Eyre TA, Kirkwood AA, Gohill S, Follows G, Waletowsa R, Walter H, et al. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: A UK wide analysis. Br J Haematol. 2019;185(4):656–69.

54. Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, et al. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome. UK multicentre restrospective study. HemaSphere. 2021;1020(S1):311.

55. Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, et al. Venetoclax consolidation after venetoclax plus obinutuzumab treatment in first-line FCR unfit patients with CLL: Primary endpoint analysis of the HOVON 139/GIVE trial. HemaSphere. 2021;5(S2):29.

56. Mato AR, Roeker LE, Eyre TA, Brander DM, Allan JN, Schuster SJ, et al. Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL): Efficacy and safety results from the MRD cohort of the phase 2 CAPTIVATE study. Blood. 2019;134(S1):35.

57. Soumerai JD, Mato A, Carter J, Dogan A, Hochberg A, Barnes JA, et al. Initial results of a multicenter, investigator-initiated study of MRD-driven time limited therapy with zanubrutinib, obinutuzumab and venetoclax. HemaSphere. 2020;4(S1):35.

58. Figueuroa MR, Rampotas A, Halperin D, Vidler J, Gavin P, Dungarwalla M, et al. Comparison of venetoclax inpatient and outpatient ramp-up strategies for CLL. UK multicentre retrospective study. HemaSphere. 2021;5(S2):292–3.

59. Bouclot F, Calleja A, Diihudy MS, Véronèse L, Pereira B, Amorim S, et al. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukaemia or Richter syndrome: a
FILO study of the French compassionate use cohort. Ann Hematol. 2021;100(4):987–93.

59. Schwaner I, Hebart H, Losem C, Wolff T, Huelsenbeck J, Schmidt B, et al. Safety and effectiveness of venetoclax in combination with rituximab in elderly patients with relapsed/refractory CLL treated under real-life conditions—data from the observational study VERVE. Hemasphere. 2021;5(S2):291–2.

60. Ferra C, Baltasar P, Terol MJ, Osorio S, Loscertales J, García Marco JA, et al. A retrospective analysis of patients with chronic lymphocytic leukemia (CLL) treated with venetoclax in the real-life setting in Spain (VENARES). Hemasphere. 2021;5(S2):712.

61. Koenig KL, Huang Y, Dotson EK, Sheredy S, Bhat SA, Byrd JC, et al. Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. Blood Adv. 2020;4(19):4860–3.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Sharman JP, Biondo JML, Boyer M, Fischer K, Hallek M, Jiang D, et al. A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. eJHaem. 2022;3:492–506. https://doi.org/10.1002/jha2.427